Abstract
There is a great emphasis on research to discover methods aimed at enhancing the efficacy of drugs and reducing their toxicity and unwanted side effects. Prodrugs are biologically inactive compounds that are converted to actual drug molecule, through biotransformation, that combine with the receptors to produce the biological action. Prodrugs can thus be considered as drugs containing specialized nontoxic protective groups utilized in a transient manner to alter or eliminate the undesirable properties of the parent drug molecule. Hypertension is one of the leading risk factors for cardiovascular disease and represents a major health and economic burden. Most of the drugs for cardiovascular diseases have low oral bioavailability, short duration of action, first pass metabolism and variable lipohilicities. Out of the need to overcome these limitations, various prodrugs have been designed for antihypertensive agents. This review extensively focuses on various strategies used for design and development of prodrugs for the various classes of antihypertensives, emphasizing on the details regarding the need for prodrug synthesis for each class, structure, type of modification and goal achieved. It also provides an insight into the major advances in the field of antihypertensive prodrug research.
Keywords: Hypertension, antihypertensive prodrug, mutual prodrug, cardiovascular diseases, prodrug synthesis, multiple cardiovascular risk factors, pharmacokinetic origin, Prodrug Design, ACE inhibitors, lisinopril, peptide prodrug, Cterminal amino acid, Temocapril hydrochloride, high potency, co-morbidities associated
Current Topics in Medicinal Chemistry
Title: Prodrug Strategies for Antihypertensives
Volume: 11 Issue: 18
Author(s): Suneela S. Dhaneshwar, Metreyi Sharma, Vivek Patel, Upasana Desai and Jiten Bhojak
Affiliation:
Keywords: Hypertension, antihypertensive prodrug, mutual prodrug, cardiovascular diseases, prodrug synthesis, multiple cardiovascular risk factors, pharmacokinetic origin, Prodrug Design, ACE inhibitors, lisinopril, peptide prodrug, Cterminal amino acid, Temocapril hydrochloride, high potency, co-morbidities associated
Abstract: There is a great emphasis on research to discover methods aimed at enhancing the efficacy of drugs and reducing their toxicity and unwanted side effects. Prodrugs are biologically inactive compounds that are converted to actual drug molecule, through biotransformation, that combine with the receptors to produce the biological action. Prodrugs can thus be considered as drugs containing specialized nontoxic protective groups utilized in a transient manner to alter or eliminate the undesirable properties of the parent drug molecule. Hypertension is one of the leading risk factors for cardiovascular disease and represents a major health and economic burden. Most of the drugs for cardiovascular diseases have low oral bioavailability, short duration of action, first pass metabolism and variable lipohilicities. Out of the need to overcome these limitations, various prodrugs have been designed for antihypertensive agents. This review extensively focuses on various strategies used for design and development of prodrugs for the various classes of antihypertensives, emphasizing on the details regarding the need for prodrug synthesis for each class, structure, type of modification and goal achieved. It also provides an insight into the major advances in the field of antihypertensive prodrug research.
Export Options
About this article
Cite this article as:
S. Dhaneshwar Suneela, Sharma Metreyi, Patel Vivek, Desai Upasana and Bhojak Jiten, Prodrug Strategies for Antihypertensives, Current Topics in Medicinal Chemistry 2011; 11 (18) . https://dx.doi.org/10.2174/156802611797183285
DOI https://dx.doi.org/10.2174/156802611797183285 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Advances in Adjuvant Therapy Against Acute Bacterial Meningitis
Current Drug Targets - Infectious Disorders Renoprotection by Direct Renin Inhibition: A Review Article and Meta-Analysis
Current Vascular Pharmacology Extracellular Hsp70: Export and Function
Current Protein & Peptide Science Premature Ovarian Insufficiency and Long-Term Health Consequences
Current Vascular Pharmacology Vascular Reactions of Iodinated X-Ray Contrast Media: Mechanisms and Possible Therapeutic Interventions
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Glatiramer Acetate Induced Hepatotoxicity
Current Drug Safety Managing Comorbidity in COPD: A Difficult Task
Current Drug Targets Predictive Genomics DNA Profiling for Athletic Performance
Recent Patents on DNA & Gene Sequences The Pleiotropic Effects of Inducible Nitric Oxide Synthase (iNOS) on the Physiology and Pathology of Penile Erection
Current Pharmaceutical Design Patent Selections
Recent Patents on Biomedical Engineering (Discontinued) Ca<sup>2+</sup>/Calmodulin-Dependent Protein Kinase- II in Vasoactive Peptide- Induced Responses and Vascular Biology
Current Vascular Pharmacology TRP Channels as Therapeutic Targets in Kidney Disease and Hypertension
Current Topics in Medicinal Chemistry Outcome of Heart Failure with Preserved Ejection Fraction: A Multicentre Spanish Registry
Current Cardiology Reviews Impact of the Renin-Angiotensin-Aldosterone-System on Cardiovascular and Renal Complications in Diabetes Mellitus
Current Vascular Pharmacology Identification of Novel Pancreatic Lipase Inhibitors Using <i>In Silico</i> Studies
Endocrine, Metabolic & Immune Disorders - Drug Targets Herbal Medicines for Diabetes Management and its Secondary Complications
Current Diabetes Reviews subject Index To Volume 1
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Military Risk Factors for Cognitive Decline, Dementia and Alzheimer’s Disease
Current Alzheimer Research Impact of the Emulsification-Diffusion Method on the Development of Pharmaceutical Nanoparticles
Recent Patents on Drug Delivery & Formulation Editorial (Thematic Issue: Immunophilins, Protein Chemistry and Cell Biology of a Promising New Class of Drug Targets – Part II)
Current Molecular Pharmacology